Psychedelics: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• LecturePsychedelics

  Franklin King

  The current state of psychedelic-assisted therapy research and its clinical implications.

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• LecturePsychedelics and Nursing: Past Wisdom, Present Science, Future Healing

  Jeffery Ramirez · Amy Berg · Carol Kottwitz

  Traces psychedelics in psychiatric treatment from historical use through current evidence and emerging nursing roles.

NEI Fall Congress 2026

November 5–8, 2026 · Colorado Springs, CO

• SymposiumPsychedelics

  Roger S. McIntyre

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• PosterFeasibility of Multimodal In Vivo Assessment of Psilocybin in Opioid Use Disorder: A Case Series

  Julia Shatalov

  Case series on feasibility of multimodal assessment of psilocybin in OUD.

  Opioid Use Disorder

• PosterHallucinogen Persisting Perception Disorder In An Adolescent: A Case Report

  Phil Dohn

  Case report of hallucinogen persisting perception disorder in an adolescent.

  Child & AdolescentSubstance Use Disorders

• PosterPsilocybin Use, Mental Health Treatment Utilization, and Unmet Treatment Need Among US Individuals with Depression

  Avery Eun

  Psilocybin use and treatment gaps among US adults with depression.

  Depression

• PosterVirtual Reality-Based Psychedelic-Like Perceptual Alterations

  Yalda Farahmand

  Explores virtual reality approaches that produce perceptual changes resembling psychedelic experiences.

  Digital Psychiatry & AI

• PosterSupplementary Pathway for Medically Monitored Ibogaine for Opioid Use Disorder: A National Semi-Markov Cost-Effectiveness Analysis

  T Wagner

  Cost-effectiveness model of medically monitored ibogaine for OUD.

  Opioid Use Disorder

See all 6 psychedelics sessions at this meeting →

NPA 32nd Annual Psychopharmacology Update 2027

February 10–13, 2027 · Las Vegas, NV

• LectureUse of Psychedelics in Severely Treatment Resistant Depression

  Scott Aaronson

  Where psychedelic-assisted treatment stands for severe treatment-resistant depression, from trial evidence to practical considerations.

  Treatment-Resistant Depression

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LecturePsychedelics

  Timothy E. Wilens

  Reviews psychedelics in the context of addiction.

  Substance Use Disorders

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SymposiumS19 – Bridging preclinical and clinical findings in psychedelic research – translational advances in psychedelic research

  Tomas Palenicek · Luisa Pinto · Sophie Holmes · Annette Johansen

  Psilocybin and ketamine effects on neurogenesis, synaptic plasticity, and the role of setting, from bench to PET imaging.

  Ketamine & EsketamineNeuroscience & Mechanisms

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• DebatePsychedelic Therapy After the Executive Order: Now What?

  Marcus Capone · Amber Capone · Matthew Zorn · Rakesh Jain · Saundra Jain · Andrew Penn · Charles Raison

  Opening-afternoon multidisciplinary panel pairing a patient's lived-experience story with a policy update on how the recent executive order and existing regulatory frameworks may shape near-term clinical use of psychedelic therapies.

  Practice, Policy & Workforce

• SymposiumMasterClass: Unlocking the Doors of Depression: Neuroplastic and Psychedelic Therapies in MDD

  Charles Raison · Andrew Penn

  Examines glutamatergic and serotonergic neuroplasticity pathways and the evidence base for investigational psychedelic and psychedelic-assisted therapies in major depression.

  DepressionNeuroscience & Mechanisms

• SymposiumMasterClass: GAD Care Reimagined: Current Best Practices and the Emerging Role of Psychedelics

  Brittany Albright · Andrew Penn

  Pairs a review of current GAD standards of care with the therapeutic rationale and emerging evidence for investigational psychedelic compounds in anxiety.

  Anxiety Disorders

• SymposiumPsychedelics in Psychiatry: Where the Evidence Stands Today and What Comes Next

  Charles Raison · Andrew Penn

  Evidence-focused update on psychedelic-assisted therapy trials, regulatory developments, and safety considerations, emphasizing separation of validated data from public enthusiasm.

  Drug Pipeline & Clinical Trials